Pharmaceutical and services group Clinigen (CLIN:AIM) is set to report a 100% rise in gross profit to approximately £44 million for the six months to 31 December 2015 on Wednesday 2 March.
The acquisition of Link Healthcare (30 Oct 2015) and rising demand for its products and services were behind the first half gains, according to a trading update on 19 January.
Investors will be scanning the forthcoming interim results for news of Link’s integration as well as that of Idis, which was bought in April 2015.
Further acquisitions are on the cards to boost its portfolio, extend its global footprint and extend the services it provides, although there is no certainty that any will be announced in the second half of the current financial year.
Analysts at Numis said in a note: 'The transformed Clinigen now offers a very joined up and global offering across the product lifecycle all the way from clinical trials through to post-approval and it was clear (on a recent conference call) that business development discussions are moving to a higher level.
'We were also reassured by the emphasis on further product acquisitions into specialty pharmaceuticals, with Link adding the potential for regional deals also.'